IR HOME NEWS & EVENTS OVERVIEW PRESS RELEASES EVENTS & PRESENTATIONS STOCK INFORMATION OVERVIEW HISTORIC STOCK LOOKUP INVESTMENT CALCULATOR ANALYST COVERAGE FINANCIALS & FILINGS OVERVIEW SEC FILINGS CORPORATE GOVERNANCE OVERVIEW LEADERSHIP BOARD OF DIRECTORS COMMITTEE COMPOSITION CONTACT IR IR HOME NEWS & EVENTS OVERVIEW PRESS RELEASES EVENTS & PRESENTATIONS STOCK INFORMATION OVERVIEW HISTORIC STOCK LOOKUP INVESTMENT CALCULATOR ANALYST COVERAGE FINANCIALS & FILINGS OVERVIEW SEC FILINGS CORPORATE GOVERNANCE OVERVIEW LEADERSHIP BOARD OF DIRECTORS COMMITTEE COMPOSITION CONTACT IR Ardelyx to Participate in Three Upcoming Investor Conferences in September Read more about Ardelyx to Participate in Three Upcoming Investor Conferences in September Ardelyx Reports Second Quarter 2020 Financial Results and Recent Business Highlights Read more about Ardelyx Reports Second Quarter 2020 Financial Results and Recent Business Highlights Ardelyx Selected as a Finalist in the Fierce Innovation Awards for the Development of its First-in-Class Product Candidate Tenapanor Read more about Ardelyx Selected as a Finalist in the Fierce Innovation Awards for the Development of its First-in-Class Product Candidate Tenapanor Ardelyx Announces Submission of New Drug Application to the U.S. FDA for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis Read more about Ardelyx Announces Submission of New Drug Application to the U.S. FDA for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis Ardelyx Announces Positive Second Data Analysis from Ongoing NORMALIZE Phase 4 Study Evaluating Tenapanor in CKD Patients on Dialysis Read more about Ardelyx Announces Positive Second Data Analysis from Ongoing NORMALIZE Phase 4 Study Evaluating Tenapanor in CKD Patients on Dialysis Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read more about Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Ardelyx Appoints Veteran Biopharma Executive, Justin Renz, as Chief Financial Officer Read more about Ardelyx Appoints Veteran Biopharma Executive, Justin Renz, as Chief Financial Officer Ardelyx to Present at the Jefferies 2020 Virtual Healthcare Conference Read more about Ardelyx to Present at the Jefferies 2020 Virtual Healthcare Conference Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read more about Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Ardelyx Strengthens Management Team with Appointment of Susan Rodriguez as Chief Commercial Officer Read more about Ardelyx Strengthens Management Team with Appointment of Susan Rodriguez as Chief Commercial Officer Pagination First page « First Previous page ‹ Previous … Page 10 Page 11 Page 12 Page 13 Current page 14 Page 15 Page 16 Page 17 Page 18 … Next page Next › Last page Last » Subscribe to FAQs Email Alerts Connect
Ardelyx to Participate in Three Upcoming Investor Conferences in September Read more about Ardelyx to Participate in Three Upcoming Investor Conferences in September
Ardelyx Reports Second Quarter 2020 Financial Results and Recent Business Highlights Read more about Ardelyx Reports Second Quarter 2020 Financial Results and Recent Business Highlights
Ardelyx Selected as a Finalist in the Fierce Innovation Awards for the Development of its First-in-Class Product Candidate Tenapanor Read more about Ardelyx Selected as a Finalist in the Fierce Innovation Awards for the Development of its First-in-Class Product Candidate Tenapanor
Ardelyx Announces Submission of New Drug Application to the U.S. FDA for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis Read more about Ardelyx Announces Submission of New Drug Application to the U.S. FDA for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
Ardelyx Announces Positive Second Data Analysis from Ongoing NORMALIZE Phase 4 Study Evaluating Tenapanor in CKD Patients on Dialysis Read more about Ardelyx Announces Positive Second Data Analysis from Ongoing NORMALIZE Phase 4 Study Evaluating Tenapanor in CKD Patients on Dialysis
Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read more about Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ardelyx Appoints Veteran Biopharma Executive, Justin Renz, as Chief Financial Officer Read more about Ardelyx Appoints Veteran Biopharma Executive, Justin Renz, as Chief Financial Officer
Ardelyx to Present at the Jefferies 2020 Virtual Healthcare Conference Read more about Ardelyx to Present at the Jefferies 2020 Virtual Healthcare Conference
Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read more about Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ardelyx Strengthens Management Team with Appointment of Susan Rodriguez as Chief Commercial Officer Read more about Ardelyx Strengthens Management Team with Appointment of Susan Rodriguez as Chief Commercial Officer